IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / / Medicus Pharma Ltd.
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports ...
Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...
The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...
Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising ...
Non-Alcoholic Steatohepatitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present ...
Veradermics raised $150 million to advance VDPHL01, an oral minoxidil treatment for hair regrowth, through Phase III trials ...
The current pharmaceutical landscape demands a change in mindset. Success requires balancing speed, cost and quality while ...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...
An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback